Purpose of CRP and D-Dimer Testing
CRP is primarily used to detect and monitor inflammation (both acute and chronic), while D-dimer is used to exclude venous thromboembolism (VTE) including pulmonary embolism (PE) and deep vein thrombosis (DVT) when combined with clinical probability assessment.
C-Reactive Protein (CRP)
Primary Clinical Applications
CRP serves as a sensitive biomarker of inflammatory activation that can distinguish between different types of inflammatory states 1:
- Normal range: Typically <3 mg/L
- Acute inflammation: Can rise above 500 mg/L during acute illness
- Chronic inflammation: Sustained elevation associated with cardiovascular disease, diabetes, depression, and other chronic conditions
Key Clinical Considerations for CRP
The traditional 10 mg/L cutoff for excluding acute pathology has limited scientific justification and may inappropriately exclude patients with chronic inflammatory conditions 1. This threshold originated from a 1981 study using outdated assay methods and should not be rigidly applied, as CRP values >10 mg/L can be associated with factors other than acute infection.
CRP cannot reliably exclude PE - even when combined with clinical probability assessment, it shows insufficient sensitivity (84%) and NPV (87-97%) for safe exclusion 2, 3.
Specific Clinical Contexts
- Periprosthetic joint infection (PJI): Combined D-dimer and CRP measurement achieves 98.11% sensitivity for chronic PJI diagnosis 4
- COVID-19 severity: Elevated CRP correlates with disease severity, particularly in diabetic patients 5, 6
- Post-surgical monitoring: CRP peaks at day 3 post-arthroplasty and returns to baseline by day 45 7
D-Dimer Testing
Primary Clinical Application
D-dimer's primary purpose is to exclude VTE, not to confirm it 8. The test has:
- High negative predictive value: Normal D-dimer effectively rules out acute PE or DVT
- Low positive predictive value: Elevated D-dimer cannot confirm PE
Critical Implementation Strategy
D-dimer testing must be combined with clinical probability assessment using validated tools (Wells score or Geneva rule) 8:
- Standard cutoff: <500 ng/mL in low-probability patients safely excludes PE
- Age-adjusted cutoff: (age × 10 μg/L for patients >50 years) increases exclusion rate from 6.4% to 30% without false negatives 8
- YEARS algorithm: Uses <1000 ng/mL cutoff in patients without clinical items, or <500 ng/mL with clinical items 8
Important Limitations
D-dimer specificity decreases to 10% in patients >80 years 8. Elevated levels are common in:
- Cancer patients
- Hospitalized patients
- Severe infection or inflammatory disease
- Pregnancy
- Post-operative states
The number needed to test rises from 3 in general emergency department populations to >10 in these specific situations 8.
Additional Clinical Applications
- Periprosthetic joint infection: D-dimer >1170 ng/mL has 92.73% sensitivity and 74.63% specificity for chronic PJI 4
- Post-surgical monitoring: Peaks at day 1 post-arthroplasty with a second smaller peak at day 15, returning to baseline by day 45 7
- COVID-19 severity: Elevated D-dimer correlates with critical illness 5, 6
- Cerebral venous thrombosis: Day 5 D-dimer >1060 mg/L associated with mortality (OR 14.63) 9
Critical Pitfall to Avoid
Never use D-dimer alone without clinical probability assessment - this leads to unnecessary imaging, costs, and complications from overdiagnosis 8. Always apply validated clinical decision rules (Wells, Geneva, or PERC criteria) before ordering D-dimer testing.